Title:
PHARMACEUTICAL COMPOSITION CONTAINING SIRT7 INHIBITOR FOR PREVENTING OR TREATING ALLERGIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2022/005012
Kind Code:
A1
Abstract:
The present invention relates to treatment and prevention of allergic diseases and, specifically, to an allergic disease immunomodulation method, which suppresses SIRT7 of nasal cavity epithelial cells to inhibit allergy mediators. The present invention suppresses SIRT7 of nasal cavity epithelial cells to inhibit the secretion of epithelial cell cytokines (TSLP), which recognize allergens to attract immune cells that induce an immune response, so that high-level processes of allergic reactions are blocked, and thus allergic diseases can be fundamentally treated and prevented.
Inventors:
KIM TAE-HOON (KR)
BYUN JUNHYOUNG (KR)
LEE KIJEONG (KR)
BYUN JUNHYOUNG (KR)
LEE KIJEONG (KR)
Application Number:
PCT/KR2021/005819
Publication Date:
January 06, 2022
Filing Date:
May 10, 2021
Export Citation:
Assignee:
UNIV KOREA RES & BUS FOUND (KR)
International Classes:
A61K48/00; A61K31/713; A61P11/06; A61P27/14; A61P37/08
Foreign References:
| CN109507430A | 2019-03-22 | |||
| KR20140123701A | 2014-10-23 | |||
| KR101915115B1 | 2018-11-05 | |||
| JP2007535518A | 2007-12-06 |
Other References:
YUAN Y., Q LIU, J ZHAO, H TANG, J SUN : "SIRT1 attenuates murine allergic rhinitis by downregulated HMGB 1/TLR4 pathway", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 87, no. 6, 30 June 2018 (2018-06-30), XP055883881, DOI: 10.1111/sji.12667
Attorney, Agent or Firm:
MUHANN PATENT & LAW FIRM (KR)
Download PDF: